A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)

By  

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY & VENEREOLOGY, Vol. 29, Iss. 2, 2015-02 ,pp. : 361-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials

By  

HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. : 1798-1808

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 475-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Patient-Reported Outcomes, Patient-Reported Information: From Randomized Controlled Trials to the Social Web and Beyond

By Baldwin Mike  

The Patient: Patient-Centered Outcomes Research, Vol. 4, Iss. 1, 2011-01 ,pp. : 11-17

Adis International

Access to resources Recommend Favorite

Impact of Certolizumab Pegol on Patient‐Reported Outcomes in Patients With Axial Spondyloarthritis

By  

ARTHRITIS CARE AND RESEARCH, Vol. 2151-464X, Iss. 10, 2015-10 ,pp. : 1475-1480

John Wiley & Sons Inc

Access to resources Recommend Favorite